Hypofractionation for Prostate Cancer: Time to Change

被引：12
作者：
Dearnaley, D. [1 ,2 ]
Syndikus, I. [3 ]
Gulliford, S. [1 ]
Hall, E. [1 ]
机构：
[1] Inst Canc Res, London, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Clatterbridge Ctr Oncol, Bebington, England
来源：
CLINICAL ONCOLOGY | 2017年 / 29卷 / 01期
关键词：
CONVENTIONALLY FRACTIONATED RADIOTHERAPY; INTENSITY-MODULATED RADIOTHERAPY; NON-INFERIORITY; OUTCOMES;
D O I：
10.1016/j.clon.2016.09.020
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3 / 5
页数：3
相关论文
共 16 条
  • [1] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Alemayehu, Wendimagegn Ghidey
    Heemsbergen, Wilma
    Heijmen, Ben
    Incrocci, Luca
    [J]. LANCET ONCOLOGY, 2016, 17 (04) : 464 - 474
  • [2] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    van Lin, Emile
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Dirkx, Maarten
    Alemayehu, Wendimagegn Ghidey
    Heijmen, Ben
    Incrocci, Luca
    [J]. LANCET ONCOLOGY, 2015, 16 (03) : 274 - 283
  • [3] Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991
    Bolla, Michel
    Maingon, Philippe
    Carrie, Christian
    Villa, Salvador
    Kitsios, Petros
    Poortmans, Philip M. P.
    Sundar, Santhanam
    van der Steen-Banasik, Elzbieta M.
    Armstrong, John
    Bosset, Jean-Francois
    Herrera, Fernanda G.
    Pieters, Bradley
    Slot, Annerie
    Bahl, Amit
    Ben-Yosef, Rahamim
    Boehmer, Dirk
    Scrase, Christopher
    Renard, Laurette
    Shash, Emad
    Coens, Corneel
    van den Bergh, Alphonsus C. M.
    Collette, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15) : 1748 - +
  • [4] Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial
    Capp, Anne
    Inostroza-Ponta, Mario
    Bill, Dana
    Moscato, Pablo
    Lai, Chi
    Christie, David
    Lamb, David
    Turner, Sandra
    Joseph, David
    Matthews, John
    Atkinson, Chris
    North, John
    Poulsen, Michael
    Spry, Nigel A.
    Tai, Keen-Hun
    Wynne, Chris
    Duchesne, Gillian
    Steigler, Allison
    Denham, James W.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2009, 90 (03) : 400 - 407
  • [5] Catton CN, 2016, J CLIN ONCOL S, V34, P5003
  • [6] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Dearnaley, David
    Syndikus, Isabel
    Mossop, Helen
    Khoo, Vincent
    Birtle, Alison
    Bloomfield, David
    Graham, John
    Kirkbride, Peter
    Logue, John
    Malik, Zafar
    Money-Kyrle, Julian
    O'Sullivan, Joe M.
    Panades, Miguel
    Parker, Chris
    Patterson, Helen
    Scrase, Christopher
    Staffurth, John
    Stockdale, Andrew
    Tremlett, Jean
    Bidmead, Margaret
    Mayles, Helen
    Naismith, Olivia
    South, Chris
    Gao, Annie
    Cruickshank, Clare
    Hassan, Shama
    Pugh, Julia
    Griffin, Clare
    Hall, Emma
    [J]. LANCET ONCOLOGY, 2016, 17 (08) : 1047 - 1060
  • [7] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
    Dearnaley, David
    Syndikus, Isabel
    Sumo, Georges
    Bidmead, Margaret
    Bloomfield, David
    Clark, Catharine
    Gao, Annie
    Hassan, Shama
    Horwich, Alan
    Huddart, Robert
    Khoo, Vincent
    Kirkbride, Peter
    Mayles, Helen
    Mayles, Philip
    Naismith, Olivia
    Parker, Chris
    Patterson, Helen
    Russell, Martin
    Scrase, Christopher
    South, Chris
    Staffurth, John
    Hall, Emma
    [J]. LANCET ONCOLOGY, 2012, 13 (01) : 43 - 54
  • [8] Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial
    Incrocci, Luca
    Wortel, Ruud C.
    Alemayehu, Wendimagegn Ghidey
    Aluwini, Shafak
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter-Paul
    de Jager, Hanja
    Heemsbergen, Wilma
    Heijmen, Ben
    Pos, Floris
    [J]. LANCET ONCOLOGY, 2016, 17 (08) : 1061 - 1069
  • [9] Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer
    Lee, W. Robert
    Dignam, James J.
    Amin, Mahul B.
    Bruner, Deborah W.
    Low, Daniel
    Swanson, Gregory P.
    Shah, Amit B.
    D'Souza, David P.
    Michalski, Jeff M.
    Dayes, Ian S.
    Seaward, Samantha A.
    Hall, William A.
    Nguyen, Paul L.
    Pisansky, Thomas M.
    Faria, Sergio L.
    Chen, Yuhchyau
    Koontz, Bridget F.
    Paulus, Rebecca
    Sandler, Howard M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) : 2325 - U39
  • [10] LATE GASTROINTESTINAL TOXICITY AFTER DOSE-ESCALATED CONFORMAL RADIOTHERAPY FOR EARLY PROSTATE CANCER: RESULTS FROM THE UK MEDICAL RESEARCH COUNCIL RT01 TRIAL (ISRCTN47772397)
    Syndikus, Isabel
    Morgan, Rachel C.
    Sydes, Matthew R.
    Graham, John D.
    Dearnaley, David P.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (03): : 773 - 783
12